We are live on ! Find out more
BGLC icon

BioNexus Gene Lab
BGLC

1 hedge funds and large institutions have $189K invested in BioNexus Gene Lab in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more capital invested

Capital invested by funds: $122K → $189K (+$67.1K)

0.78% more ownership

Funds ownership: 1.24% → 2.02% (+0.78%)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
+$158K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$41.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DS
1
DRW Securities
Illinois
$189K +$158K +33,179 +226%
UBS Group
2
UBS Group
Switzerland
– -$41.7K -7,626 Closed

BGLC Hedge Fund Activity: Q4 2025 in Review

1 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q4 2025, worth a combined $189K — up 55% from $122K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BGLC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was DRW Securities, adding an estimated $158K. The largest seller was UBS Group, exiting entirely with an estimated $41.7K sold.

  • 1 institutional investor held BioNexus Gene Lab (BGLC) as of Q4 2025, down from 2 in Q3 2025.
  • Funds reported $189K of BioNexus Gene Lab stock for Q4 2025, up 55% quarter-over-quarter.
  • 0 funds opened new BioNexus Gene Lab positions in Q4 2025 and 1 closed out, a net change of -1 holder.
  • The largest BioNexus Gene Lab buyer in Q4 2025 was DRW Securities, an estimated $158K added.
  • The largest BioNexus Gene Lab seller in Q4 2025 was UBS Group, an estimated $41.7K sold.

Based on aggregated 13F filings for Q4 2025.